Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
30 11 2022
30 11 2022
Historique:
received:
11
06
2022
accepted:
22
11
2022
entrez:
30
11
2022
pubmed:
1
12
2022
medline:
3
12
2022
Statut:
epublish
Résumé
The SARS-CoV-2 Omicron (B.1.1.529) variant has been associated with less severe acute disease, however, concerns remain as to whether long-term complaints persist to a similar extent as for earlier variants. Studying 1 323 145 persons aged 18-70 years living in Norway with and without SARS-CoV-2 infection in a prospective cohort study, we found that individuals infected with Omicron had a similar risk of post-covid complaints (fatigue, cough, heart palpitations, shortness of breath and anxiety/depression) as individuals infected with Delta (B.1.617.2), from 14 to up to 126 days after testing positive, both in the acute (14 to 29 days), sub-acute (30 to 89 days) and chronic post-covid (≥90 days) phases. However, at ≥90 days after testing positive, individuals infected with Omicron had a lower risk of having any complaint (43 (95%CI = 14 to 72) fewer per 10,000), as well as a lower risk of musculoskeletal pain (23 (95%CI = 2-43) fewer per 10,000) than individuals infected with Delta. Our findings suggest that the acute and sub-acute burden of post-covid complaints on health services is similar for Omicron and Delta. The chronic burden may be lower for Omicron vs Delta when considering musculoskeletal pain, but not when considering other typical post-covid complaints.
Identifiants
pubmed: 36450749
doi: 10.1038/s41467-022-35240-2
pii: 10.1038/s41467-022-35240-2
pmc: PMC9709355
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7363Informations de copyright
© 2022. The Author(s).
Références
EClinicalMedicine. 2021 Aug;38:101019
pubmed: 34308300
Stat Med. 2014 Nov 30;33(27):4681-94
pubmed: 25060703
JAMA. 2022 Feb 8;327(6):583-584
pubmed: 34967859
PLoS One. 2021 Oct 8;16(10):e0257926
pubmed: 34624023
BMJ. 2022 Jan 17;376:e066809
pubmed: 35039315
Curr Control Trials Cardiovasc Med. 2002 Jan 8;3(1):4
pubmed: 11985778
Nat Commun. 2022 Apr 12;13(1):1957
pubmed: 35413949
Lancet Infect Dis. 2021 Oct;21(10):1373-1382
pubmed: 33984263
Stat Methods Med Res. 2018 Feb;27(2):323-335
pubmed: 26988930
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
Thorax. 2021 Apr;76(4):405-407
pubmed: 33273028
JAMA. 2022 Apr 26;327(16):1610-1611
pubmed: 35254379
JAMA. 2020 Apr 14;323(14):1401-1402
pubmed: 32167523
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937